Well, um, yeah, no, it's fantastic. I mean, I'm excited, uh, just like our patients are. We, we have something. Um, specific to, that's approved, and we can say, hey, there's great data behind this, you should use this. Um, so I think this anti-inflammatory approach with the Brunswickcades, um, uh, a really, really important development, uh, for, for us. Um, we need more data around some of the things we do, like, you know, hypertonic saline and airway clearance. I mean, we tell lots of patients to do it. Uh, there's really a posse of data to support doing it, so we need, you know, better evidence there. Although it seems intuitive and we think people will benefit and do benefit from it. Um, we shouldn't forget inhaled antibiotics. I, again, there's, there's plenty of trial data out there supporting, Um, various antibiotics usage in that way. Um, I think, you know, I'm still hopeful we'll have, uh, an FDA approved inhaled antibiotics at some point. Uh, but it, it's still important and, and, you know, Brinza's going to drop people's exacerbations 20, 25%. So, I mean, some of these people are still exacerbating multiple times per year, even with that benefit. So, they're going to need another approach to, um, to help control their disease. Um, we have a pipeline now, which is exciting, and, um, You know, there are some other modalities in development. There's other, uh, anti-DPP1 drugs out there. There are, um, other inhaled compounds coming that, um, Yeah, ziphentrine that's, uh, approved for COPD is now being trialed in bronchiectasis. It's a phosphodiesterase inhibitor. Um, there are therapies coming that break apart biofilm or prevent biofilm, uh, buildup in the airway that are exciting. There's other adjunctive therapies that, you know, are antibody, uh, IgG molecules that help the body destroy pseudomonas or, uh, kill pseudomonas in the airway. Uh, boy, I can think of, there's phases. There's a whole, there's a whole host of therapies out there, um, that are being looked at. So, so I suspect that, um, this is just the start, really, in terms of this anti-inflammatory approach. I think there'll be other drugs out there that, that, that go along that axis. I think we'll have more, uh, antimicrobial approaches as well. Um, and, um, yeah, I, uh, 10 years from now, maybe, We'll have 10 therapies, all of which cost $200,000 a year. I'm just kidding. I don't know. You know how it goes with these new therapies, but, but I do think it's exciting, and I am hopeful in 5 or 10 years we have a host of choices for patients and. Uh, and some patients may need more, more than one of these drugs, uh, but, but again, uh, or in some cases, you know, we see this with other inflammatory diseases, therapy stopped working and you got to go to something else with the same or different, uh, mechanism of action. So, I, I look forward to the day when we have those type of choices for our patients and we can better control this disease.
Presenter
